“South Africa has become the largest user of lenacapavir (LEN), the world’s newest HIV prevention injection, with over 31,000 people enrolled in just six weeks. While uptake is overwhelmingly positive, early rollout data highlights inequities in access and questions about sustainability before cheaper generics arrive.”
On 5 June 2026, South Africa began rolling out lenacapavir (LEN), a twice-yearly HIV prevention injection hailed as a potential game-changer in the fight against AIDS. Just six weeks later, the country accounts for more than half of Africa’s LEN users, positioning itself as a leader in HIV prevention innovation. But beneath the headline numbers lies a complex story of success, inequity, and looming challenges.
Uptake and Demand
- 31,297 South Africans are already using LEN, out of Africa’s total 60,000 users.
- 98.5% of HIV-negative individuals offered a choice between the daily prevention pill and LEN opted for the injection.
- Uptake has been strongest in Gauteng and KwaZulu-Natal, which together host nearly half of South Africa’s population and the majority of clinics offering LEN.
This overwhelming preference suggests that convenience—two injections per year versus daily pills—is a decisive factor in adoption.
Equity Concerns
Despite the strong uptake, rollout data reveals disparities:
- Only 360 government clinics (about 8% of the total) currently offer LEN.
- Rural provinces lag behind, with limited access compared to urban centers.
- Younger populations and women appear more likely to adopt LEN, while older men remain underrepresented.
These gaps raise concerns about whether LEN will reach the most vulnerable groups, including those historically underserved by HIV prevention programs.
Public Perception and Hesitancy
Health Minister Aaron Motsoaledi acknowledged initial fears that vaccine hesitancy—lingering from COVID-19—might affect LEN uptake. Some South Africans mistakenly associated the injection with vaccines. However, rollout data shows that these concerns have largely been overcome, with demand far exceeding expectations.
Supply and Sustainability
South Africa’s LEN program currently relies on donated doses, raising questions about sustainability:
- Analysts warn that demand may outpace supply before generic versions become available.
- Manufacturing LEN locally could be a solution, but this requires investment in pharmaceutical infrastructure and regulatory approval.
- Without generics, the cost of LEN may limit long-term accessibility, especially in lower-income communities.
Global and Regional Context
South Africa’s rollout is being closely watched across Africa:
- Neighboring countries are considering LEN adoption but face resource constraints.
- At the International AIDS Conference in Rio de Janeiro, South Africa showcased its rollout data, positioning itself as a continental leader in HIV prevention.
- Experts argue that South Africa’s experience could serve as a blueprint for other nations, provided lessons on equity and sustainability are addressed.
Expert Opinions
- Mia Malan (Bhekisisa): “The real story isn’t the numbers—it’s what they reveal about who is choosing LEN and who is being left behind.”
- Linda Pretorius (Health Analyst): “LEN is attracting new users who never engaged with HIV prevention before, but we must ensure it doesn’t simply replace the daily pill for those already protected.”
Conclusion
South Africa’s LEN rollout represents a historic milestone in HIV prevention, with early data showing remarkable uptake and enthusiasm. Yet the challenges of equity, sustainability, and supply remain pressing. If addressed, LEN could reshape the trajectory of HIV prevention not only in South Africa but across Africa. If not, the promise of LEN risks being undermined by the same structural barriers that have long plagued public health interventions.
